The USPTO issued a memorandum to the examining corps entitled Recent Subject Matter Eligibility Rulings (Rapid Litigation Management v. CellzDirect and Sequenom v. Ariosa) on July 14, 2016.
The U.S. Patent and Trademark Office (“USPTO”) has proposed a rule change that would enable it to conduct random audits of affidavits or declarations of use filed under sections 8 and 71 of the Trademark Act as a permanent extension of the pilot program.
On July 14, 2016, the PTO sent a memorandum to the examining corps regarding the recent rulings in Rapid Litigation Management Ltd. v. Cellzdirect, Inc., Appeal No. 2015-1570 (Fed. Cir. July 5, 2016), and Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371 (Fed. Cir. 2015), cert. denied, No. 15-1102, 2016 WL 1117246 (June 27, 2016).
On July 14, 2016, the USPTO issued a Memorandum to the Patent Examining Corps on patent eligibility in view of recent court decisions.
It is a widely accepted reality that obtaining a federal trademark registration for use on cannabis-related goods presents a host of unique challenges, but what aren’t widely discussed are the United States Patent and Trademark Office’s (USPTO) reasons for rejecting many cannabis trademark applications.
Medical marijuana is currently legal in 25 states, including four states that have also legalized recreational use (Alaska, Colorado, Oregon, and Washington).
In response to President Obama’s National Cancer Moonshot initiative to eliminate cancer, the USPTO has launched the “Cancer Immunotherapy Pilot Program.”
The USPTO has launched a new after final program available starting today, July 11, 2016.